539 related articles for article (PubMed ID: 17965108)
1. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy.
Arevalo JF; Maia M; Flynn HW; Saravia M; Avery RL; Wu L; Eid Farah M; Pieramici DJ; Berrocal MH; Sanchez JG
Br J Ophthalmol; 2008 Feb; 92(2):213-6. PubMed ID: 17965108
[TBL] [Abstract][Full Text] [Related]
2. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment.
Oshima Y; Shima C; Wakabayashi T; Kusaka S; Shiraga F; Ohji M; Tano Y
Ophthalmology; 2009 May; 116(5):927-38. PubMed ID: 19269033
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up.
Arevalo JF; Wu L; Sanchez JG; Maia M; Saravia MJ; Fernandez CF; Evans T
Eye (Lond); 2009 Jan; 23(1):117-23. PubMed ID: 17891058
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).
Jorge R; Costa RA; Calucci D; Cintra LP; Scott IU
Retina; 2006; 26(9):1006-13. PubMed ID: 17151487
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial.
Ahmadieh H; Shoeibi N; Entezari M; Monshizadeh R
Ophthalmology; 2009 Oct; 116(10):1943-8. PubMed ID: 19699531
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy.
di Lauro R; De Ruggiero P; di Lauro R; di Lauro MT; Romano MR
Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):785-91. PubMed ID: 20135139
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy.
Yang CS; Hung KC; Huang YM; Hsu WM
J Ocul Pharmacol Ther; 2013; 29(6):550-5. PubMed ID: 23495932
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema.
Mirshahi A; Shenazandi H; Lashay A; Faghihi H; Alimahmoudi A; Dianat S
Retina; 2010 Feb; 30(2):254-9. PubMed ID: 20057344
[TBL] [Abstract][Full Text] [Related]
10. Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy.
Liu L; Wu WC; Yeung L; Wang NK; Kuo YH; Chao AN; Chen KJ; Chen TL; Lai CC; Hwang YS; Chen YP
Ophthalmic Surg Lasers Imaging; 2010; 41(1):72-7. PubMed ID: 20128573
[TBL] [Abstract][Full Text] [Related]
11. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
[TBL] [Abstract][Full Text] [Related]
12. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery.
Takamura Y; Kubo E; Akagi Y
Ophthalmology; 2009 Jun; 116(6):1151-7. PubMed ID: 19376589
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
15. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; RodrÃguez FJ; Udaondo-Mirete P;
Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results.
Arevalo JF; Maia M; Garcia-Amaris RA; Roca JA; Sanchez JG; Berrocal MH; Wu L;
Ophthalmology; 2009 Aug; 116(8):1481-7, 1487.e1. PubMed ID: 19545901
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy.
Minnella AM; Savastano CM; Ziccardi L; Scupola A; Falsini B; Balestrazzi E
Acta Ophthalmol; 2008 Sep; 86(6):683-7. PubMed ID: 17995986
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy.
Mason JO; Nixon PA; White MF
Am J Ophthalmol; 2006 Oct; 142(4):685-8. PubMed ID: 17011869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
